





To the Editor: The commentary, by Dr. M. S.
Cetron and colleagues, on the action plan for drug-
resistant Streptococcus pneumoniae (1) prompts us
to describe the main system for surveillance of anti-
biotic resistance in use by the Public Health Labora-
tory Service (PHLS) in England and Wales and our
recent results for resistance in S. pneumoniae.
Since 1974, the diagnostic laboratories in the
PHLS network (53 in 1993-94) and increasing num-
bers of National Health Service and private labora-
tories have reported, on a voluntary basis, all
bacterial isolations from blood or cerebrospinal fluid
to the PHLS Communicable Disease Surveillance
Centre. Since 1989, they have been asked to include
their antimicrobial susceptibility test results on all
isolates. In 1993, for example, antimicrobial suscep-
tibility test results were received from 195 laborato-
ries, on > 28,000 nonduplicate isolates. Some data are
sent as written entries on the report forms, but
increasingly they are being transmitted electroni-
cally. Results may be analyzed according to region or
reporting laboratory or by patient characteristics,
such as age.
All laboratories do not test the same antimicrobial
agents, but a nucleus set is tested by most laborato-
ries for each species. Results are reported as “suscep-
tible” (S), “resistant” (R) or “intermediate” (I).
Although the methods are not standardized, exter-
nal quality assurance is provided by the UK National
External Quality Assessment Scheme (2), to which
almost all laboratories subscribe. In addition, many
laboratories refer isolates that show particularly
critical resistance traits (such as ß-lactam resistance
in S. pneumoniae, or glycopeptide resistance in En-
terococcus species) to the PHLS Antibiotic Reference
Unit (ARU) for determination of minimum inhibi-
tory concentrations (MICs); these can often be
matched against the submitted results. Occasional
prevalence surveys in the PHLS network, with test-
ing of isolates in the ARU, act as a further monitoring
measure.
The application of the system can be seen in the
recently published results of 6 years’ surveillance of
resistance amongst isolates of S. pneumoniae caus-
ing bacteremia or meningitis (3,4). There has been a
statistically significant trend to increased resistance
to penicillin (from 0.3% in 1989 to 2.5% in 1994),
although these are low percentages in comparison
with those seen in many other countries (5). More-
over, a considerable increase has been observed in
resistance to erythromycin (from 3.3% in 1989 to
11.2% in 1994). These figures are based on
susceptibility testing of more than 2,500 isolates in
each of the 6 years. In 1993, resistance to penicillin
and erythromycin was significantly more common
amongst pneumococci from bacteremia and menin-
gitis in the younger age groups (£ 9 years). A signifi-
cant rise during the 6 years was also seen in
trimethoprim resistance, but no significant change
was observed in resistance to tetracycline or
chloramphenicol.
The resistance totals include isolates reported as
resistant (R), and as intermediate (I), as we cannot
be sure of the basis for this discrimination in the
diagnostic laboratories. The proportion of isolates
reported as I is very small, with the exception of
antimicrobial agents for which many strains have
MICs near the breakpoint defined to separate sensi-
tive and resistant strains. In the case of S. pneumo-
niae, this applied to trimethoprim (6.3% of isolates
reported as I in 1993); < 0.5% of isolates were re-
ported as I to other antimicrobial agents.
The results of the National External Quality As-
sessment Scheme exercises have shown acceptable
proficiency. For example, in the detection of penicil-
lin resistance, in five distributions of pneumococcal
strains that require an MIC of 0.25 mg/l, 74% to 90%
of laboratories obtained correct results; in six distri-
butions of strains that require an MIC of 1.0 mg/l.
95% to 99% of laboratories did so (J.J.S. Snell, pers.
comm.). The isolates included in the analysis that
were also tested in the ARU gave closely similar
results: for example, of 86 pneumococcal isolates
tested for susceptibility to penicillin in early 1995,
82 (95%) gave the same result in the sender’s labo-
ratory and in the ARU. A survey of resistance in
pneumococci (from all sites) conducted in March l995
with MIC determination by the ARU (unpublished)
showed similar proportions of resistant strains.
These observations demonstrate that the results
of susceptibility tests undertaken for the manage-
ment of individual patients may be compiled and
analyzed for surveillance purposes. Duplicate iso-
lates from the same infection episode should not be
included, and satisfactory quality assurance should
be undertaken. Increasing use of computers and
networking among the clinical laboratories should
facilitate the process of data collection.
David C.E. Speller, Alan P. Johnson, Barry D.
Cookson, Pauline Waight,* Robert C. George
Central Public Health Laboratory and *Communicable
Disease Surveillance Centre, 61 Colindale Avenue,
London NW9 5HT, UK
Letter
Vol. 2, No. 1 Å January-March 1996 57 Emerging Infectious DiseasesReferences
1. Cetron MS, Jernigan DB, Breiman RF, DSRP Working
Group. Action plan for drug-resistant Streptococcus
pneumoniae. Emerging Infectious Diseases 1995;1:64-
5.
2. Snell JJS, de Mello JV, Gardner PS. The United King-
dom national microbiological quality assessment
scheme. J Clin Pathol 1982;35:82-93.
3. Aszkenazy OM, George RC, Begg NT. Pneumococcal
bacteraemia and meningitis in England and Wales
1982 to 1992. CDR Review 1995;5:R45-R50.
4. Antibiotic resistance in Streptococcus pneumonia 1993
and 1994. Commun Dis Rep 1995;5:187-8.
5. Friedland IR, McCracken GH. Management of infec-
tions caused by antibiotic-resistant Streptococcus pneu-
moniae. N Engl J Med 1994;331;377-82.
Letter
Emerging Infectious Diseases 58 Vol. 2, No. 1 Å January-March 1996